Home > Press > Dr. Geoffrey S. Ginsburg joins VisEn Medical's scientific advisory board
Heritage in Genomic Profiling and Molecular Medicine Tightly Linked with
VisEn's Molecular Imaging Technology Platforms and Development Programs
VisEn Medical, Inc., a leader in fluorescence in vivo imaging of biologic and molecular activities from research through medicine, today announced that Geoffrey S. Ginsburg, M.D., Ph.D. has joined its Scientific Advisory Board.
Dr. Geoffrey S. Ginsburg joins VisEn Medical's scientific advisory board
Woburn, MA | Posted on December 8th, 2006
Dr. Ginsburg is Professor of Medicine and Pathology and Director of the Center for Genomic Medicine at Duke University's Institute for Genome Sciences & Policy. Dr. Ginsburg's work centers on the identification and application of predictive biomarkers in developing and applying novel therapies and for improved research and clinical medicine.
VisEn's fluorescence imaging technologies provide the industry's most robust imaging performance in identifying, characterizing and quantifying a range of biomarkers in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular and bone disease. By imaging these disease-related biological activities in vivo, VisEn's technology platforms enable expanded areas of research, more efficient drug development, and truly tailored clinical medicine into the future.
Kirtland G. Poss, President and Chief Executive Officer of VisEn commented on the announcement, "Dr. Ginsburg's deep heritage and expertise in genomics, biomarkers, pharmaceutical development and personalized medicine builds directly into VisEn's mission of developing and applying fluorescence imaging technologies from in vivo research through clinical medicine. We are honored by his participation with VisEn and see this as yet another key foundation for our company's leadership in clinically directed molecular imaging."
Dr. Ginsburg stated, "The future of clinical medicine will be built around linked understandings, readouts and treatments of disease-related biomarkers in patient populations. VisEn's real-time in vivo imaging of biologic and molecular processes is playing an increasingly central role in basic research and drug development today, and there is a close parallel between these approaches and the advanced molecular profiling work being carried out at our center."
"By bringing together the industry experts and leaders in the fields of genomics, biomarkers, imaging and therapeutic intervention, we will work to produce new approaches to pharmaceutical development and personalized medicine that will have a truly positive impact on healthcare delivery," added Dr. Ginsburg. "I look forward to collaborating even more deeply with VisEn's
leading Scientific Advisory Board to further advance this promising new area of medicine."
Prior to his academic career, Dr. Ginsburg was Director of Cardiovascular Disease and Vice President of Molecular and Personalized Medicine at Millennium Pharmaceuticals. In these roles, he was responsible for Millennium's personalized medicine initiatives to develop biomarkers for disease
and pharmacogenomic strategies for therapeutics and their implementation in the drug development process. His responsibilities also included translational research efforts and strategic academic alliances required to integrate genomics into the practice of medicine.
About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed at the Massachusetts General Hospital and
Harvard Medical School. VisEn is developing today's highest performing
fluorescence molecular imaging technology platforms, from research through
medicine. VisEn also works directly with its partners to design ranges of
tailored probes and applications that are targeted to their specific research
areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and
has been financed by leading venture firms including Flagship Ventures and
The Bollard Group. For further information please visit http://www.visenmedical.com.
For more information, please click here
Copyright © VisEn Medical, Inc.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nano-supercapacitors for electric cars July 25th, 2014
New imaging agent provides better picture of the gut July 25th, 2014
Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster: University of Leicester research team unlocks insights into creation of new nano-materials July 25th, 2014
Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer July 25th, 2014
Malvern Instruments completes acquisition of MicroCal and announces purchase of Archimedes product from Affinity Biosensors July 25th, 2014
Hysitron is Awarded TWO R&D 100 Awards for Highly Innovative Technology Developments in the Areas of Extreme Environments and Biological Mechanical Property Testing July 23rd, 2014
The Hiden EQP Plasma Diagnostic with on-board MCA July 22nd, 2014
Nanometrics Announces Upcoming Investor Events July 22nd, 2014
Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014
NSS Pays Tribute to Space Pioneer Frederick I. Ordway III July 7th, 2014
Harris & Harris Group Announces Changes to Its Legal Department June 9th, 2014
SEMATECH Appoints Satyavolu Papa Rao to Lead Process Technology May 13th, 2014
Japanese gold leaf artists worked on a nano-scale: Study demonstrates X-ray fluorescence spectroscopy is a non-destructive way to date artwork July 3rd, 2014
Harry Potter-style invisibility cloaks: A real possibility next Christmas? Forget socks and shaving foam, the big kids of tomorrow want an invisible cloak for Christmas December 19th, 2013
Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants December 12th, 2013
ZEISS Microscopes used to create images for Art Exhibit at Midway Airport: Art of Science: Images from the Institute for Genomic Biology October 25th, 2013